16 December 2017 in International Journal of Clinical Pharmacy
1 May 2013 in The American Journal of Emergency Medicine
15 March 2017 in Journal of Pharmacy Practice
We aim to describe our experience with the four-factor prothrombin complex concentrates (4F-PCC) Kcentra® at differing doses in patients with liver cirrhosis requiring emergent hemostasis in the setting of major or life-threatening bleeding. An automated query of patients who received Kcentra between January 2014 and March 2016 was performed. Patients who had clinically significant bleeding and received Kcentra for treatment of coagulopathy of chronic liver disease (CCLD) were included in the study. Baseline patient demographics, administration indication, pertinent laboratory values, and other reversal therapies were collected. Four patients met inclusion for analysis. One patient presented with hemopericardium, cardiac tamponade, and shock, and 3 patients presented with intracranial hemorrhage. Each patient experienced an improvement in international normalized ratio (INR) and at least a period of clinical hemostasis after Kcentra administration without complications referable to Kcentra. Kcentra may be a safe, rapid, and effective treatment option for hemorrhagic emergencies associated with CCLD. Further research is needed to determine the ideal monitoring and dosing regimen for use in CCLD.
1 June 2020 in Journal of Global Antimicrobial Resistance
19 April 2023 in Research Square
Background: Atrial fibrillation with rapid ventricular response (Afib-RVR) is a hemodynamically unstable arrythmia encountered in the critically ill patient. Digoxin, a cardiac glycoside, may be an appropriate treatment option for managing Afib-RVR with contraindications or unresponsiveness to traditional agents. Currently, there is limited guidance for the use of digoxin supported with continuous renal replacement therapy (CRRT). Aim: The primary outcome of this study is the incidence of bradycardia (Heart rate less than 60 beats per minute) within 48 hours following digoxin initiation. Secondary outcomes include the time to achieve rate control after digoxin initiation and the proportion of time rate controlled within the first 48 hours of digoxin therapy. Methods: This was a retrospective study of patients admitted to an intensive care unit between March 2018 and October 2021 with a diagnosis of Afib-RVR, received a digoxin loading dose while supported with CRRT. Exclusion criteria included prior digoxin use, use other than Afib-RVR concurrent beta-blocker or calcium-channel blocker therapy. Results: Nine patients met the inclusion criteria, there were no incidences of bradycardia within the first 48 hours following digoxin initiation. The median digoxin loading dose, time to rate control and proportion with rate control was 9.01 ± 2.04 mcg/kg, 7±13 hours and 54 ± 23% respectively. Conclusions: In our cohort of patients in Afib-RVR loaded with digoxin while supported on CRRT did not experience any bradycardic episodes. This data supports a cautious approach to digoxin use in this patient population and serves as a platform for future studies for the optimal dosing regimen.
9 May 2023 in Research Square
Background: Hypertriglyceridemia-induced pancreatitis (HTGP) is defined as pancreatitis associated with serum triglyceride (TG) levels exceeding 1,000 mg/dL. Current guidelines are lacking in regards to the optimum dose of high-dose insulin infusion (HDII). Aim: We sought to describe our institutional HDII experience for the treatment of HTGP. Method: This was a retrospective, single-center study of patients admitted to the medical intensive care unit between 9/1/2018 and 9/30/2020. Baseline patient characteristics, HDII dose and duration, TG response and use of rescue dextrose or potassium interventions were collected. Patients were excluded if they received therapeutic anticoagulation, plasmapheresis, or an insulin infusion not for HTGP. The primary outcome was the insulin infusion dose and the duration of HDII in relation to the change in serum TG levels. Secondary outcomes included the incidence of hypokalemic and hypoglycemic events. Results: Twelve patients were included in the study. The median admission TG level was 2889.5 mg/dL with a subsequent decrease of 56% at the 24 hour time mark. The median starting dose was 0.09 units/kg/hr which remained stable throughout the treatment period. The median infusion duration was 51.5 hours. Hypokalemia was more common than hypoglycemia, however HDII was not discontinued due to any side effects. Conclusion: Initiating HDII at approximately 0.1 units/kg/hr for HTGP is a safe and effective dose. Half of the patients responded by approximately the 48th hour. Judicious monitoring of serum potassium, glucose and maintenance fluids were required to avoid side effects. Further research comparing different HDII dosages is warranted.